Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous stem cells + platelet rich plasma
- Development stage
- Unknown
- Lead developer
- Arthrex
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular, Intralesional, Percutaneous
01
Overview
This combination therapy involves the use of a patient's own (autologous) stem cells—typically mesenchymal stem cells (MSCs) derived from bone marrow aspirate concentrate (BMAC) or adipose tissue—in conjunction with platelet-rich plasma (PRP). PRP acts as a bioactive scaffold and a source of concentrated growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF), which stimulate the proliferation, migration, and differentiation of the co-administered stem cells. The stem cells provide a reservoir of regenerative cells capable of tissue repair, extracellular matrix synthesis, and immunomodulation. This synergistic approach is widely investigated in regenerative medicine for orthopedic conditions such as osteoarthritis and tendon injuries, as well as in wound healing and aesthetic medicine, aiming to accelerate tissue repair and modulate the inflammatory environment.
- Other names
- ASC + PRPBMAC + PRPADSC + PRPStem cell-enriched PRPAutologous mesenchymal stem cells and platelet-rich plasma
Beyond the preview
Go deeper on autologous stem cells + platelet rich plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous stem cells + platelet rich plasma.